Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRGX

CARGO Therapeutics Inc

Dec 05 • 04:00PM ET

15.71

Dollar change +0.07
Percentage change 0.45	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-	Insider Own	34.39%	Shs Outstand	38.67M	Perf Week	2.15%
Market Cap	607.51M	Forward P/E	-	EPS next Y	-	Insider Trans	25.08%	Shs Float	25.37M	Perf Month	-
Income	-	PEG	-	EPS next Q	-1.47	Inst Own	27.49%	Short Float / Ratio	1.70% / 1.39	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.43M	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	28.33	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	13.14 - 17.29	Perf YTD	8.12%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-9.14%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	0.00%	Gross Margin	-	52W Low	19.56%	ATR	1.00
Employees	-	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	-	Volatility	8.49% -
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.36	Prev Close	15.64
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	308.66K	Price	15.71
Recom	1.00	SMA20	4.83%	SMA50	4.83%	SMA200	4.83%	Volume	111,701	Change	0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-23	Initiated	Truist	Buy	$34
Dec-05-23	Initiated	TD Cowen	Outperform
Dec-05-23	Initiated	JP Morgan	Overweight	$23
Dec-05-23	Initiated	Jefferies	Buy	$28

Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Third Rock Ventures V, L.P.	10% Owner	Nov 14	Buy	15.00	1,333,333	19,999,995	1,807,119	Nov 14 07:08 PM
PERCEPTIVE ADVISORS LLC	Former 10% Owner	Nov 14	Buy	15.00	666,666	9,999,990	2,912,835	Nov 14 04:32 PM
Samsara BioCapital GP, LLC	10% Owner	Nov 14	Buy	15.00	666,666	9,999,990	4,121,689	Nov 16 07:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRGX

CARGO Therapeutics Inc

Upgrade your FINVIZ experience